This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My File Cabinet Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Keyserling, H. L. Articles by Jarvis, W. R. Search for Related Content PubMed PubMed Citation Articles by Keyserling, H. L. Articles by Jarvis, W. R. Related Collections Therapeutics & Toxicology Social Bookmarking                         What's this?

PEDIATRICS Vol. 112 No. 2 August 2003, pp. e104-e111

ELECTRONIC ARTICLE

Vancomycin Use in Hospitalized Pediatric Patients

Harry L. Keyserling, MD^*, Ronda L. Sinkowitz-Cochran, MPH, James M. Harris, II, MS, Gail L. Levine, MA, Jane D. Siegel, MD^¶, Beth H. Stover, RN, CIC^||, Sharon A. Lau, AB, MS^**, William R. Jarvis, MD the Pediatric Prevention Network

^* Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia
Division of Healthcare Quality Promotion, CDC, Atlanta, Georgia
NACHRI, Alexandria, Virginia
^¶ University of Texas Southwestern Medical Center, Dallas, Texas
^|| Kosair Children’s Hospital, Louisville, Kentucky
^** MMP, Inc, Los Angeles, California

Objectives. To assess vancomycin utilization at children’s hospitals, to determine risk factors for vancomycin use and length of therapy, and to facilitate adapting recommendations to optimize vancomycin prescribing practices in pediatric patients.

Methods. Two surveys were conducted at Pediatric Prevention Network hospitals. The first (Survey I) evaluated vancomycin control programs. The second (Survey II) prospectively reviewed individual patient records. Each hospital was asked to complete questionnaires on 25 consecutive patients or all patients for whom vancomycin was prescribed during a 1-month period.

Results. In Survey I, 55 of 65 (85%) hospitals reported their vancomycin control policies. Three quarters had specific policies in place to restrict vancomycin use. One half had at least 3 vancomycin restriction measures. In Survey II, personnel at 22 hospitals reviewed 416 vancomycin courses, with 2 to 25 (median = 12) patients tracked per hospital. Eighty-two percent of the vancomycin prescribed was for treatment of neonatal sepsis, fever/neutropenia, fever of unknown origin, positive blood culture, pneumonia, or meningitis. In an additional 6% (26/416), vancomycin was prescribed for patients with ß-lactam allergies and in 13% (56/416) for prophylaxis. Median duration of prophylaxis was 2 days (range: 1–15 days). Almost half (196, 47%) of the patients who received vancomycin were in intensive care units; 27% of the vancomycin courses were initiated by neonatologists and 19% by hematologists/oncologists. The predominant risk factor at the time of vancomycin initiation was the presence of vascular catheters (322, 77%); other host factors included cancer chemotherapy (55, 13%), transplant (30, 7%), shock (24, 6%), other immunosuppressant therapy (17, 4%), or hyposplenic state (2, <1%). Other clinical considerations were severity of illness (96, 23%), uncertainty about diagnosis (51, 12%), patient not responding to current antibiotic therapy (40, 10%), or implant infection (13, 3%). When vancomycin was initiated, blood cultures were positive in 85 patients (20%); cultures from other sites were positive in 45 (11%), and Gram stains of body fluids were positive in 37 (9%). In 29 (7%) patients, organisms sensitive only to vancomycin were isolated before vancomycin initiation. Reasons for discontinuing vancomycin included: therapeutic course completed (125, 30%), negative cultures (106, 25%), alternative antibiotics initiated (75, 18%), illness resolved (14, 3%), or patient expired (13, 3%). Final results of blood culture isolates resistant to ß-lactam antibiotics included 48 coagulase-negative staphylococcus, 5 Staphylococcus aureus, and 10 other species.

Conclusions. At children’s hospitals, vancomycin is initiated for therapy in patients who have vascular catheters and compromised host factors. Only 7% had laboratory-confirmed ß-lactam-resistant organisms isolated at the time vancomycin was prescribed. Efforts to modify empiric vancomycin use in children’s hospitals should be targeted at intensivists, neonatologists, and hematologists. Initiatives to decrease length of therapy by decreasing the number of surgical prophylaxis doses and days of therapy before laboratory results may decrease vancomycin exposure.

---

Key Words: vancomycin • pediatrics • antimicrobial resistance • antimicrobial use

Abbreviations: MRSA, methicillin-resistant Staphylococcus aureus • VRE, vancomycin-resistant enterococci • HICPAC, Hospital Infection Control Practices Advisory Committee • CDC, Centers for Disease Control and Prevention • PPN, Pediatric Prevention Network • NACHRI, National Association of Children’s Hospitals and Related Institutions • MMP, Medical Management Planning • NICU, neonatal intensive care unit • CONS, coagulase-negative staphylococcal species

---

Received for publication Aug 8, 2002; Accepted Apr 7, 2003.

CiteULike    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				J. K. Todd Staphylococcal Infections Pediatr. Rev., December 1, 2005; 26(12): 444 - 450. [Full Text] [PDF]